DB-959 SODIUM

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H26NO5.Na
Molecular Weight	443.4674
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CCC1=C(CCOC2=CC=C3[C@H](CC([O-])=O)CCC3=C2)N=C(O1)C4=CC=C(OC)C=C4

InChI

InChIKey=ICCAFCVDQOALPN-FERBBOLQSA-M

InChI=1S/C25H27NO5.Na/c1-3-23-22(26-25(31-23)16-6-8-19(29-2)9-7-16)12-13-30-20-10-11-21-17(14-20)4-5-18(21)15-24(27)28;/h6-11,14,18H,3-5,12-13,15H2,1-2H3,(H,27,28);/q;+1/p-1/t18-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C25H26NO5
Molecular Weight	420.4776
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:47:53 GMT 2023` Edited by `admin` on `Fri Dec 15 19:47:53 GMT 2023`
Record UNII	YZ6UUQ5JUZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DB-959 SODIUM

Code

English

1H-INDENE-1-ACETIC ACID, 5-(2-(5-ETHYL-2-(4-METHOXYPHENYL)-4-OXAZOLYL)ETHOXY)-2,3-DIHYDRO-, SODIUM SALT (1:1), (1S)-

Systematic Name

English

T3D-959 SODIUM SALT

Code

English

DB-959 SODIUM SALT

Code

English

Code System Code Type Description

FDA UNII

YZ6UUQ5JUZ

Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023

PRIMARY

PUBCHEM

49839871

Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023

PRIMARY

CAS

1258076-66-2

Created by admin on Fri Dec 15 19:47:53 GMT 2023 , Edited by admin on Fri Dec 15 19:47:53 GMT 2023

PRIMARY

Related Record Type Details


					4TW7R18VOJ

DB-959

PARENT -> SALT/SOLVATE

Related Record Type Details


					YZ6UUQ5JUZ

DB-959 SODIUM

ACTIVE MOIETY

Comments:

Originator: Bayer HealthCare Pharmaceuticals; Developer: DARA BioSciences, T3D Therapeutics; Class: Antihyperglycaemic, Insulin sensitiser, Small molecule; Mechanism of Action: Peroxisome proliferator-activated receptor delta agonist, Peroxisome proliferator-activated receptor gamma agonist; Highest Development Phases: Phase I/II Alzheimer's disease, Discontinued for Dyslipidaemia, Type 2 diabetes mellitus; Most Recent Events: 01 Jul 2015 Phase-I/II clinical trials in Alzheimer's disease (In the elderly, In adults) in USA (PO) (NCT02560753), 18 Jun 2013 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO), 18 Jun 2013 Discontinued - Phase-I for Dyslipidaemias in USA (PO)